Back to search
Stage II-IIIB Non-small Cell Lung Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Stage II-IIIB Non-small Cell Lung Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Stage II-IIIB Non-small Cell Lung Carcinoma trials you may qualify forThis phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small c…
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant p…
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving patholog…
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating pat…
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell…
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults wi…
This study compares the outcomes and safety of two standard treatment options called microwave ablation and surgical wedge resection in patients with non-small…
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell…